Related references
Note: Only part of the references are listed.Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
Hong Yang et al.
CANCER RESEARCH (2012)
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
Sergey I. Nikolaev et al.
NATURE GENETICS (2012)
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
F. Xing et al.
ONCOGENE (2012)
Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition
W. Deng et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Mutant BRAF Melanomas-Dependence and Resistance
Poulikos I. Poulikakos et al.
CANCER CELL (2011)
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
Hubing Shi et al.
CANCER RESEARCH (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
Current Status of Targeted Therapies for Mantle Cell Lymphoma
Julie E. Chang et al.
DRUGS (2011)
mTOR Inhibitors in Advanced Renal Cell Carcinoma
Martin H. Voss et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2011)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
mTOR links oncogenic signaling to tumor cell metabolism
Jessica L. Yecies et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
Ana M. Gonzalez-Angulo et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling
Y. Lu et al.
ONCOGENE (2011)
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Vanessa S. Rodrik-Outmezguine et al.
CANCER DISCOVERY (2011)
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
Lydia W. T. Cheung et al.
CANCER DISCOVERY (2011)
Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics
Scott E. Woodman et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors
Kyle A. Edgar et al.
CANCER RESEARCH (2010)
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
Hong Yang et al.
CANCER RESEARCH (2010)
Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
Y. N. Vashisht Gopal et al.
CANCER RESEARCH (2010)
From man to mouse and back again: advances in defining tumor AKTivities in vivo
David F. Restuccia et al.
DISEASE MODELS & MECHANISMS (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors
R. Kefford et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mutations in GNA11 in Uveal Melanoma.
Catherine D. Van Raamsdonk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis
C. Nogueira et al.
ONCOGENE (2010)
Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors
Jannik N. Andersen et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Krishna M. Vasudevan et al.
CANCER CELL (2009)
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Michael A. Davies et al.
CLINICAL CANCER RESEARCH (2009)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Catherine D. Van Raamsdonk et al.
NATURE (2009)
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Todd D. Prickett et al.
NATURE GENETICS (2009)
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort et al.
NATURE GENETICS (2009)
Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
Bijay S. Jaiswal et al.
PLOS ONE (2009)
A novel AKT3 mutation in melanoma tumours and cell lines
M. A. Davies et al.
BRITISH JOURNAL OF CANCER (2008)
Akt and mutant V600EB-Raf cooperate to promote early melanoma development
Mitchefl Cheung et al.
CANCER RESEARCH (2008)
MicroRNA expression profiling in human ovarian cancer:: miR-214 induces cell survival and cisplatin resistance by targeting PTEN
Hua Yang et al.
CANCER RESEARCH (2008)
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Ultraviolet radiation and melanoma: A systematic review and analysis of reported sequence variants
Thomas Hocker et al.
HUMAN MUTATION (2007)
BRAF and NRAS mutations in melanoma and melanocytic nevi
Jenny N. Poynter et al.
MELANOMA RESEARCH (2006)
Epigenetic silencing of the PTEN gene in melanoma
Alireza Mirmohammadsadegh et al.
CANCER RESEARCH (2006)
PI3-kinase subunits are infrequent somatic targets in melanoma
John A. Curtin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Mutations of PIK3CA are rare in cutaneous melanoma
K Omholt et al.
MELANOMA RESEARCH (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma
Vikas K. Goel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition
HY Irie et al.
JOURNAL OF CELL BIOLOGY (2005)
Growing roles for the mTOR pathway
DD Sarbassov et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
CCI-779 in metastatic melanoma - A phase II trial of the California Cancer Consortium
K Margolin et al.
CANCER (2005)
Oncogenic Ras in tumour progression and metastasis
K Giehl
BIOLOGICAL CHEMISTRY (2005)
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma
EE Patton et al.
CURRENT BIOLOGY (2005)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
H Tsao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
B-RAF is a therapeutic target in melanoma
M Karasarides et al.
ONCOGENE (2004)
Deregulated Akt3 activity promotes development of malignant melanoma
JM Stahl et al.
CANCER RESEARCH (2004)
PTEN signaling pathways in melanoma
H Wu et al.
ONCOGENE (2003)
High frequency of BRAF mutations in nevi
PM Pollock et al.
NATURE GENETICS (2003)
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
CA Grimes et al.
PROGRESS IN NEUROBIOLOGY (2001)
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation
XP Zhou et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
